The courts reversed certain key guidance documents issued by the Health Resources and Services Administration for the 340B Program, which raises uncertainty.
Anil Shankar, Adria Warren, and Jordan Smiley
Advertisement
Articles by Anil Shankar, Adria Warren, and Jordan Smiley
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Novo Nordisk’s Bloomington Plant Receives FDA OAI Designation Following Contamination and Compliance Issues
2
United States Delays Tariffs on Singapore’s Pharma Exports Amid Ongoing Trade Negotiations
3
Pharma Pulse: FDA Approves One-Minute HIV Test, US Delays Pharma Tariffs, and CVS Acquires 600 Rite Aid Stores
4
Pharma Pulse: Kaiser Permanente Strike Escalates, Takeda Partners with Nabla Bio, and FDA Flags Novo Nordisk Bloomington Site
5
